Technology
Health
Medical

Neovasc

$0.461
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0129 (-2.73%) Today
+$0.002 (0.44%) After Hours

Why Robinhood?

You can buy or sell Neovasc and other stocks, options, ETFs, and crypto commission-free!

About

Neovasc, Inc. engages in the development, manufacture, and marketing of medical devices for the cardiovascular marketplace. Its products includes Neovast Tiara and Neovasc Reducer. Read More The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Employees
110
Headquarters
Richmond, British Columbia
Founded
2000
Market Cap
9.18M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.11M
High Today
$0.475
Low Today
$0.458
Open Price
$0.47
Volume
751.54K
52 Week High
$12.50
52 Week Low
$0.4231

Collections

Technology
Health
Medical
Advertising and Marketing
Medical Devices
Business Services
Canada
North America

News

PR NewswireFeb 20

Micro Interventional Devices, Inc. Reaches Settlement Agreement with Neovasc, Inc.

NEWTOWN, Pa., Feb. 20, 2019 /PRNewswire/ -- Micro Interventional Devices, Inc. ("MID") announced today that it is has entered into a Settlement Agreement with Neovasc, Inc. MID (the "Plaintiffs") filed a lawsuit in September 2018 in the U.S. District Court for the District of New Jersey including certain disputed allegations relating to Neovasc's transcatheter mitral valve replacement (TMVR) technology including the Tiara™ device. The Settlement Agreement includes settlement fees in installments totaling US...

4,742

Earnings

-$0.70
-$0.48
-$0.26
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.05 per share
Actual
Available Mar 21, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.